Lilly

Company Snapshot

Founded: 1876
Entity Type: Public
Employees: 47,000
Region: U.S.
Revenue: $45,042.7 Millions
Revenue Year: 2024
Segment: Biologics and insulin
Headquarter: Indiana, U.S.
Key Geographics: Europe, U.S., Japan, China
Corporate Address: Lilly Corporate Center, Indianapolis, Indiana 46285 U.S. Tel. +1- 317-276-2000 www.lilly.com

Company Overview

Eli Lilly and Co. is a U.S. pharmaceutical company founded in 1876. Headquartered in Indianapolis, Indiana, Eli Lilly and Co. is globally recognized for its contributions to the healthcare industry. The company research, develops, manufactures and markets a diverse range of pharmaceutical products.

The company is known for its expertise in diabetes, oncology, immunology, neurology and cardiovascular diseases. Notable products include insulin medications like Humalog, oncology drugs like Alimta, and antidepressants like Prozac (many products are available, but not all, but major are mentioned in the product portfolio table). As a significant player in the pharmaceutical sector, Eli Lilly and Co. is committed to innovation, patient well-being and community engagement.

Financial Highlights (FY 2024)

Net Revenue: ***
Total Current Liabilities: ***
Total Current Assets: ***
R&D expenses: ***
Operating Income: ***

This information is available for BCC Research members only.

Lilly In Reports

Immunotherapy Drugs: Global Markets

Our Research report provides an overview of the immunotherapy drugs market report analyzes the market trends of immunotherapy drugs with data from 2024, estimates from 2025, projections of compound annual growth rates...

Therapies for Rheumatoid Arthritis: Technologies and Global Markets

BCC Research expert says the Therapies for Rheumatoid Arthritis market report analyzes the market trends of therapies for rheumatoid arthritis with data from 2024, estimates from 2025, projections of CAGR through 2030. ...

Global Irritable Bowel Syndrome and Inflammatory Bowel Disease Therapeutics Market

BCC Research Market Analyst says global market for irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD) therapeutics is expected to grow from $33.3 billion in 2025.

Company's Business Segments

  • Net Product Revenue : Revenue related to products company sell pursuant to these arrangements is included in net product revenue.
  • Collaboration and other revenue : Revenue recognized from collaborations and other arrangements includes company share of profits from the collaborations, as well as royalties, upfront and milestone payments received under these types of contracts.

Applications/End User Industries

  • Diabetes Centers
  • Diabetes Clinics
  • Diabetes Management
  • Oncologists
  • Hematologists
  • Biopharmaceutical
  • Cancer Research and Development
  • Rheumatologists
  • Dermatologists
  • Immunologists
  • Autoimmune Diseases Clinics
  • Psychiatrists
  • Neuroscience Clinics
  • Psychologists Centers
  • Psychiatric Departments
  • Urologists
  • Cardiologists
  • Infectious Disease Specialists
  • Gastroenterologists
  • Pulmonologists
AI Sentiment